GlaxoSmithKline (GSK) said on Wednesday that it released a study on Nucala (mepolizumab) that treats severe eosinophilic asthma in the Asia-Pacific Society for Respirology (APSR) 2022 at Coex, southern Seoul, from Nov. 17-20.Professor Ian Pavord from the University of Oxford made a presentation on r
Reyon Pharmaceutical said on Thursday that it signed a memorandum of understanding (MOU) with Therabest on business cooperation based on the supply of plasmid DNA (pDNA) samples for the development of natural killer (NK) cell therapy.Under the MOU, Therabest will exchange information with Reyon to p
Boryung (formerly Boryung Pharmaceutical) is going all out for the domestic launch of Finjuve Spray, or “sprinkling Propecia,” a hair loss treatment based on finasteride.Boryung plans to release Finjuve Spray next March or April, jumping into the domestic hair loss treatment market as early as the f
HER2-positive breast cancer, which accounts for 20-25 percent of breast cancer, has been known for poor treatment prognosis, as its tumor cells proliferate and metastasize actively and recur quickly even after treatment.However, the cure rate of HER2-positive breast cancer, especially in its early s
JW Pharmaceutical said its U.S. research institute, JW Theriac, moved from San Diego to Cambridge Innovation Center (CIC) in Boston in the U.S.CIC is the world's renowned bio-health industry cluster where over 1,000 global pharmaceutical firms, rising start-ups, hospitals, and research institutions
SK Bioscience shares plummeted Wednesday morning after the company admitted that it had suspended production of SKYCovione, the first domestically developed Covid-19 vaccine.At 12:00 p.m., on Wednesday, SK Bioscience shares stood at 79,500 won ($58.80), down 8.3 from the previous trading day.News re
The one-year grace period granted by the financial regulator to Dx&Vx, a molecular diagnostics company, to improve business irregularities has ended.According to the Korea Exchange (KRX), the improvement period for Dx&Vx ended on Tuesday.Now, Dx&Vx must submit documents detailing how it implemented
Ildong Pharmaceutical said that Japan's Ministry of Health, Labour and Welfare has granted emergency use approval (EUA) for Shionogi & Co’s Xocova, an oral Covid-19 treatment Ildong has been co-developing.Shionogi applied for conditional approval for Xocova to Japan's Ministry of Health, Labor and W
Celltrion Healthcare said multi-country real-world data proved the effectiveness and safety of Truxima (ingredient: rituximab, CT-P10), an anticancer biosimilar, in non-Hodgkin’s lymphoma (NHL) patients. EJHaem, an international academic journal, published a study of the effectiveness and safety of
Takeda Pharmaceutical Korea has proven the efficacy and safety of Ninlaro, a multiple myeloma treatment (ingredient: ixazomib), in Koreans through real-world data.The study included 60 patients who received Ninlaro in combination with two other treatments (ixazomib + lenalidomide + dexamethasone) at
GSK has decided to voluntarily withdraw Juluca (dolutegravir/rilpivirine), the company’s first-ever two-drug regimen of HIV treatment, three years and nine months after it won the permit in Korea.According to the Ministry of Food and Drug Safety, GSK withdrew the permit of Juluca Tab. on Monday.Acco
Janssen Korea and Illumina Korea are considering trimming their payroll, following the moves of other Korean offshoots of multinational pharmaceutical firms.According to industry sources, Janssen Korea is trying to reduce its workforce through an early retirement program (ERP)."I have heard that our
Wells Bio, a subsidiary of Access Bio, said on Tuesday that it has recently obtained approval from the Ministry of Food and Drug Safety (MFDS) for its kit that can diagnose tsutsugamushi bacterial infections.Tsutsugamushi is an acute febrile disease transmitted by larvae of chigger mites carrying ts
It may be safe to say that the development of PARP (Poly ADP-ribose polymerase) inhibitors has changed the treatment environment for ovarian cancer. That’s because the development extended the progression-free survival period and other prognoses of ovarian cancer patients.After it was known that PAR
ImmuneMed has won the approval for the domestic clinical trial of its candidate substance for a Covid-19 cure, hzVCFG-v13 (burfiralimab).Last Friday, the Ministry of Food and Drug Safety gave the go-ahead to Korea's phase 2/3 clinical trial. The company plans to assess the efficacy and safety of the
Yuyu Pharmaceutical unveiled its plans to conduct U.S. and EU clinical trials for using dutasteride to treat androgenetic alopecia (AGA) during the World Congress for Hair Research 2022 held in Melbourne, Australia, from Friday to Monday.The trial aims to improve patient convenience by reducing the
Moderna started to receive recognition as a messenger RNA (mRNA) powerhouse after developing an effective Covid-19 vaccine less than a year after the Covid-19 pandemic first started.However, with the Covid-19 pandemic becoming more of an endemic than a pandemic, both industry watchers and investors
Korean conglomerates are jumping into the bio-industry after seeing success from predecessors, including Samsung and SK.Most recently, Orion Holdings, the holding company of the Orion Group, decided to start the bio business in earnest by establishing Orion Biologics.In a public filing, Orion Holdin
JW Pharmaceutical said on Friday that its oral renal anemia drug, Enaroy (ingredient: enarodustat), obtained license approval from the Ministry of Food and Drug Safety (MFDS).Renal anemia is one of the complications of chronic kidney disease, and is caused by poor differentiation and proliferation o
Celltrion said on Friday that it won the first trial of two patents (Patent No. US 9254338, US 9669069) against Regeneron, a leading biotechnology company in the United States.The lawsuit regards a U.S. patent on the treatment of angiogenic ophthalmic diseases of Eylea (ingredient: aflibercept), an